The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: The search for the sweet spot in heart failure

JAMA Cardiology

Volumn 2, Issue 9, 2017, Pages 939-940

  Verma, Subodh ^a   McMurray, John J V ^b   Cherney, David Z I ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; URIC ACID;

BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DIURETIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; KIDNEY BLOOD FLOW; MACROALBUMINURIA; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SHORT SURVEY;

EID: 85030655315     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.1891     Document Type: Short Survey

References (7)

1. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
2. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
3. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events. Diabetologia. 2016;59(7):1333-1339.
4. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial. Diabetes Care. 2016;39(7):1108-1114.
5. Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis. Cell Metab. 2016;24(2):200-202.
6. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes Diabetes Care. 2016;39(12):e212-e213.
7. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860-1870.